Healthcare
Live Price
Offline$13.34
+1.44% today
1Y Change
+36.82%
Window
Jun 30, 2025 → Jun 26, 2026
Coverage: 249 bars · Jun 30, 2025 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Astellas Pharma Inc. (ALPMY) is a Healthcare stock with a market cap of $3.95T. The stock last traded around $13.34 and up 36.8% across the available one-year price window (Jun 30, 2025 → Jun 26, 2026). Baseline metrics include revenue growth of +18.6%, EPS growth of +508.7%, a dividend yield of 3.5%. What stands out right now is revenue +18.6%, EPS +508.7%, free cash flow +293.1% with operating margin 18.9% and ROIC 12.1%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 13.6 and price/sales 1.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ALPMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
ALPMY is 18.83 pts ahead over the shared 1Y window.
ALPMY had 12.50 pts deeper max drawdown than SPY.
ALPMY beat SPY in 1 of 2 calendar years shown and trailed in 1.
ALPMY
+36.82%
Normalized return
SPY
+17.99%
S&P 500
Excess Return
+18.83 pts
Relative to SPY
ALPMY Max Drawdown
-21.63%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for ALPMY and SPY.
| Year | ALPMY | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +0.15% | +6.71% | -6.56 pts | SPY |
| 2025 | +37.03% | +11.19% | +25.83 pts | ALPMY |
Unable to load analyst forecasts.
Timed out loading forecasts for ALPMY
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.